# Job F M Van Boven

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8314808/job-f-m-van-boven-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| 121                | 14,634                | 32          | 120            |
|--------------------|-----------------------|-------------|----------------|
| papers             | citations             | h-index     | g-index        |
| 151<br>ext. papers | 19,138 ext. citations | 8.4 avg, IF | 5.4<br>L-index |

| #   | Paper  | IF               | Citations |
|-----|--|------------------|-----------|
| 121 | Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Patients With Tuberculosis: Systematic Review of Randomized Controlled Trials <i>Journal of Medical Internet Research</i> , <b>2022</b> , 24, e33062                                       | 7.6              | 3         |
| 120 | Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise <i>Npj Primary Care Respiratory Medicine</i> , <b>2022</b> , 32, 6   | 3.2              | 0         |
| 119 | Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2022</b> ,   | 5.4              | 3         |
| 118 | Improved health status of severe COPD patients after being included in an integrated primary care service: A prospective cohort study <i>European Journal of General Practice</i> , <b>2022</b> , 28, 66-74  | 2.8              |           |
| 117 | Prioritising respiratory research needs in primary care: results from the International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise <b>2021</b> ,  |                  | 2         |
| 116 | Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-Based Cohort Study from UK Primary Care. <i>Journal of Asthma and Allergy</i> , <b>2021</b> , 14, 1375-1388   | 3.1              | 1         |
| 115 | European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 748702  | 5.6              | 3         |
| 114 | Clinical Characteristics, Treatment Patterns and Economic Burden of COPD in Kyrgyzstan: A FRESH AIR Study. <i>International Journal of COPD</i> , <b>2021</b> , 16, 2833-2843  | 3                | O         |
| 113 | Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A Scoping Review of Their Applicability for Medication Adherence and Therapeutic Drug Monitoring. <i>Drugs</i> , <b>2021</b> , 81, 1983-2  | 002 <sup>1</sup> | 1         |
| 112 | Recovery from COVID-19: a sprint or marathon? 6-month follow-up data from online long COVID-19 support group members. <i>ERJ Open Research</i> , <b>2021</b> , 7,  | 3.5              | 21        |
| 111 | GINA 2020: Potential Impacts, Opportunities, and Challenges for Primary Care. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 1516-1519  | 5.4              | 4         |
| 110 | Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT). <i>Diabetes Care</i> , <b>2021</b> , 44, 1419-1425          | 14.6             | 3         |
| 109 | Centers. Frontiers in Pharmacology, <b>2021</b> , 12, 652018   | 5.6              | O         |
| 108 | Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical | 7·4              | О         |
| 107 | Outcomes. Journal of Pragmatic and Observational Research, 2021, 12, 25-35  Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting. BMJ Open, 2021, 11, e042417  | 3                | 2         |
| 106 | Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 3846-3864                                  | 2.6              | 6         |
| 105 | A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 68569   | 6 <sup>5.6</sup> | 6         |

## (2020-2021)

| 1 | 04 | Personalized Medication Adherence Management in Asthma and Chronic Obstructive Pulmonary Disease: A Review of Effective Interventions and Development of a Practical Adherence Toolkit.<br>Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3979-3994                                  | 5.4  | 5   |
|---|----|---|------|-----|
| 1 | 03 | Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 3997-4004   | 5.4  | 12  |
| 1 | 02 | Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. <i>Chest</i> , <b>2021</b> , 159, 58-72   | 5.3  | 8   |
| 1 | 01 | Effectiveness of a targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: A cluster randomised controlled trial. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 2032-2042              | 3.8  | 5   |
| 1 | 00 | Gaps in COPD Guidelines of Low- and Middle-Income Countries: A Systematic Scoping Review. <i>Chest</i> , <b>2021</b> , 159, 575-584   | 5.3  | 15  |
| 9 | 9  | Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 923-935                                    | 4    | 2   |
| 9 | 8  | Work absence in patients with asthma and/or COPD: a population-based study. <i>Npj Primary Care Respiratory Medicine</i> , <b>2021</b> , 31, 9  | 3.2  | 2   |
| 9 | 7  | Challenges in the Implementation of Chronic Obstructive Pulmonary Disease Guidelines in Lowand Middle-Income Countries: An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 1269-1277   | 4.7  | 5   |
| 9 | 6  | Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> ,   | 2.6  | 2   |
| 9 | 5  | When biology meets behaviour: can medication adherence mask the contribution of pharmacogenetic effects in asthma?. <i>European Respiratory Journal</i> , <b>2021</b> , 58,   | 13.6 | 2   |
| 9 | 4  | Impact of Blood Eosinophil Variability in Asthma: A Real-Life Population Study. <i>Annals of the American Thoracic Society</i> , <b>2021</b> ,  | 4.7  | 3   |
| 9 | 3  | Strategies for the prevention, diagnosis and treatment of COPD in low- and middle- income countries: the importance of primary care. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1563-1577   | 3.8  | 1   |
| 9 | 2  | Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studies. <i>Npj Primary Care Respiratory Medicine</i> , <b>2020</b> , 30, 21   | 3.2  | 21  |
| 9 | 1  | Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine,the</i> , <b>2020</b> , 8, 585-596  | 35.1 | 334 |
| 9 | 0  | Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2020</b> , 39, 1513-1525 | 5.3  | 9   |
| 8 | 9  | Prevalence of Seasonal Influenza Vaccination in Chronic Obstructive Pulmonary Disease (COPD) Patients in the Balearic Islands (Spain) and Its Effect on COPD Exacerbations: A Population-Based Retrospective Cohort Study. International Journal of Environmental Research and Public Health,           | 4.6  | 2   |
| 8 | 8  | Trajectory Analyses of Adherence Patterns in a Real-Life Moderate to Severe Asthma Population.<br>Journal of Allergy and Clinical Immunology: in Practice, <b>2020</b> , 8, 1961-1969.e6  | 5.4  | 17  |
| 8 | 7  | Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. <i>Clinical and Translational Allergy</i> , <b>2020</b> , 10, 1  | 5.2  | 51  |

| 86 | Prevalence and Economic Burden of Respiratory Diseases in Central Asia and Russia: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,  | 4.6  | 3  |
|----|---|------|----|
| 85 | A personalised screening strategy for diabetic retinopathy: a cost-effectiveness perspective. <i>Diabetologia</i> , <b>2020</b> , 63, 2452-2461   | 10.3 | 5  |
| 84 | Switching Inhalers: A Practical Approach to Keep on UR RADAR. <i>Pulmonary Therapy</i> , <b>2020</b> , 6, 381-392   | 3    | 5  |
| 83 | Implementing a context-driven awareness programme addressing household air pollution and tobacco: a FRESH AIR study. <i>Npj Primary Care Respiratory Medicine</i> , <b>2020</b> , 30, 42  | 3.2  | 3  |
| 82 | Critical review of multimorbidity outcome measures suitable for low-income and middle-income country settings: perspectives from the Global Alliance for Chronic Diseases (GACD) researchers. <i>BMJ Open</i> , <b>2020</b> , 10, e037079               | 3    | 8  |
| 81 | Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2020</b> , 20, 437-453   | 2.2  | 42 |
| 80 | Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia. <i>Respirology</i> , <b>2020</b> , 25, 543-551   | 3.6  | 12 |
| 79 | Targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: study protocol of a cluster randomised controlled trial. <i>BMJ Open</i> , <b>2020</b> , 10, e034507 | 3    | 4  |
| 78 | Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial. <i>Thorax</i> , <b>2020</b> , 75, 244-252   | 7.3  | 46 |
| 77 | User Acceptability and Technical Robustness Evaluation of a Novel Smart Pill Bottle Prototype Designed to Support Medication Adherence. <i>Patient Preference and Adherence</i> , <b>2020</b> , 14, 625-634   | 2.4  | 7  |
| 76 | Predicting short- and long-term glycated haemoglobin response after insulin initiation in patients with type 2 diabetes mellitus using machine-learning algorithms. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2704-2711               | 6.7  | 10 |
| 75 | Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221856   | 3.7  | 4  |
| 74 | Smart Medication Adherence Monitoring in Clinical Drug Trials: A Prerequisite for Personalised Medicine?. <i>EClinicalMedicine</i> , <b>2019</b> , 15, 3-4  | 11.3 | 11 |
| 73 | ACO: Time to move from the description of different phenotypes to the treatable traits. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210915  | 3.7  | 27 |
| 72 | Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 1143-1150  | 4.7  | 23 |
| 71 | Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA. <i>Respirology</i> , <b>2019</b> , 24, 972-979   | 3.6  | 6  |
| 70 | Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1407-1417  | 3.8  | 7  |
| 69 | Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients.  Clinical Infectious Diseases, 2019, 68, 1482-1493   | 11.6 | 44 |

### (2018-2019)

| 68 | Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. <i>Value in Health</i> , <b>2019</b> , 22, 1092-1101 | 3.3            | 6    |
|----|---|----------------|------|
| 67 | Effects and acceptability of implementing improved cookstoves and heaters to reduce household air pollution: a FRESH AIR study. <i>Npj Primary Care Respiratory Medicine</i> , <b>2019</b> , 29, 32                               | 3.2            | 15   |
| 66 | Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-  | 3 <b>58</b> .4 | 87   |
| 65 | The socioeconomic burden of chronic lung disease in low-resource settings across the globe - an observational FRESH AIR study. <i>Respiratory Research</i> , <b>2019</b> , 20, 291  | 7.3            | 17   |
| 64 | Making sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economists. <i>European Respiratory Journal</i> , <b>2019</b> , 53,   | 13.6           | 11   |
| 63 | An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 60, 54-70   | 3.9            | 14   |
| 62 | Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 934-942  | 5.4            | 8    |
| 61 | High COPD prevalence at high altitude: does household air pollution play a role?. <i>European Respiratory Journal</i> , <b>2019</b> , 53,   | 13.6           | 24   |
| 60 | Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 578-588.e2   | 5.4            | 20   |
| 59 | HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups. <i>Diabetes, Obesity and Metabolism,</i> <b>2018</b> , 20, 1957-1964                     | 6.7            | 8    |
| 58 | Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 785-793   | 5.4            | 42   |
| 57 | The Clinical Impact of Different Adherence Behaviors in Patients with Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 1630-1633              | 10.2           | 23   |
| 56 | Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 619-632   | 5.4            | 11   |
| 55 | Burden and risk factors for community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. <i>European Respiratory Journal</i> , <b>2018</b> , 52,  | 13.6           | 56   |
| 54 | Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis. <i>Npj Primary Care Respiratory Medicine</i> , <b>2018</b> , 28, 24                      | 3.2            | 15   |
| 53 | Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji. <i>BMC Health Services Research</i> , <b>2018</b> , 18, 218                           | 2.9            | 6    |
| 52 | Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 957-971   | 4.4            | 48   |
| 51 | Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2018</b> , 392, 1015-1035   | 40             | 1171 |

| 50 | The burden of disease in Greece, health loss, risk factors, and health financing, 2000-16: an analysis of the Global Burden of Disease Study 2016. <i>Lancet Public Health, The</i> , <b>2018</b> , 3, e395-e406  | 22.4 | 24   |
|----|---|------|------|
| 49 | Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , <b>2018</b> , 63, 177-186  | 4    | 19   |
| 48 | Global Alliance for Chronic Disease researchersSstatement on multimorbidity. <i>The Lancet Global Health</i> , <b>2018</b> , 6, e1270-e1271   | 13.6 | 24   |
| 47 | Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. <i>BMJ Open</i> , <b>2018</b> , 8, e022051  | 3    | 1    |
| 46 | Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2018</b> , 391, 2236-2271  | 40   | 381  |
| 45 | Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. <i>Journal of Medical Economics</i> , <b>2017</b> , 20, 503-509  | 2.4  | 8    |
| 44 | Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. <i>Respiratory Research</i> , <b>2017</b> , 18, 31   | 7.3  | 53   |
| 43 | Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review. <i>Npj Primary Care Respiratory Medicine</i> , <b>2017</b> , 27, 24  | 3.2  | 65   |
| 42 | Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2017</b> , 390, 231-266   | 40   | 352  |
| 41 | In patients with severe uncontrolled asthma, does knowledge of adherence and inhaler technique using electronic monitoring improve clinical decision making? A protocol for a randomised controlled trial. <i>BMJ Open</i> , <b>2017</b> , 7, e015367   | 3    | 18   |
| 40 | Electric scooters: batteries in the battle against ambient air pollution?. <i>Lancet Planetary Health, The</i> , <b>2017</b> , 1, e168-e169   | 9.8  | 3    |
| 39 | Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population. <i>Respiratory Research</i> , <b>2017</b> , 18, 206   | 7.3  | 5    |
| 38 | Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study. <i>Journal of Pragmatic and Observational Research</i> , <b>2017</b> , 8, 31-41  | 7.4  | 2    |
| 37 | Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1084-1150   | 40   | 421  |
| 36 | Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1260-1344 | 40   | 1152 |
| 35 | Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1151-1210  | 40   | 2542 |
| 34 | Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1211-1259                                    | 40   | 3432 |
| 33 | Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1345-1422                   | 40   | 1378 |

### (2015-2017)

| 32 | Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1423-1459   | 40                       | 224  |
|----|--|--------------------------|------|
| 31 | Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Respiratory Medicine,the</i> , <b>2017</b> , 5, 691-706 | 35.1                     | 1119 |
| 30 | Optimizing identification and management of COPD patients - reviewing the role of the community pharmacist. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 192-201  | 3.8                      | 30   |
| 29 | Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 43-63   | 4.4                      | 32   |
| 28 | Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, 1364-1376   | 25.5                     | 77   |
| 27 | Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up. <i>Multidisciplinary Respiratory Medicine</i> , <b>2016</b> , 11, 39  | 3                        |      |
| 26 | Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence. <i>Respiratory Medicine</i> , <b>2016</b> , 110, 34-45   | 4.6                      | 13   |
| 25 | Comorbidome, Pattern, and Impact of Asthma-COPD Overlap Syndrome in Real Life. <i>Chest</i> , <b>2016</b> , 149, 1011-20   | 5.3                      | 94   |
| 24 | Effects of targeting disease and medication management interventions towards patients with COPD. <i>Current Medical Research and Opinion</i> , <b>2016</b> , 32, 229-39  | 2.5                      | 11   |
| 23 | Higher Adherence During Reimbursement of Pharmacological Smoking Cessation Treatments. <i>Nicotine and Tobacco Research</i> , <b>2016</b> , 18, 56-63  | 4.9                      | 9    |
| 22 | Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands. <i>International Journal of COPD</i> , <b>2016</b> , 11, 2191-2201   | 3                        | 14   |
| 21 | Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. <i>PLoS ONE</i> , <b>2016</b> , 11, e0146262  | 3.7                      | 62   |
| 20 | Enhancing the use of Asthma and COPD Assessment Tools in Balearic Primary Care (ACATIB): a region-wide cluster-controlled implementation trial. <i>Npj Primary Care Respiratory Medicine</i> , <b>2016</b> , 26, 16003   | 3.2                      | 7    |
| 19 | What We Mean When We Talk About Adherence in Respiratory Medicine. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2016</b> , 4, 802-12  | 5.4                      | 74   |
| 18 | Enhancing Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness Considerations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2016</b> , 4, 835-4   | 4 <i>6</i> <sup>.4</sup> | 44   |
| 17 | Factors associated with inhaled corticosteroids prescription in primary care patients with COPD: A cross-sectional study in the Balearic Islands (Spain). <i>European Journal of General Practice</i> , <b>2016</b> , 22, 232  | -2 <del>3</del> 8        | 5    |
| 16 | COPD case finding: effective, but also cost-effective?. Lancet Respiratory Medicine, the, 2016, 4, e49   | 35.1                     | 2    |
| 15 | Mapping the clinical chronic obstructive pulmonary disease questionnaire onto generic preference-based EQ-5D values. <i>Value in Health</i> , <b>2015</b> , 18, 299-307  | 3.3                      | 14   |

| 14 | Towards tailored and targeted adherence assessment to optimise asthma management. <i>Npj Primary Care Respiratory Medicine</i> , <b>2015</b> , 25, 15046   | 3.2 | 35  |
|----|--|-----|-----|
| 13 | Predictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocol. <i>Npj Primary Care Respiratory Medicine</i> , <b>2015</b> , 25, 15051  | 3.2 | 6   |
| 12 | Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands. <i>Drugs and Aging</i> , <b>2014</b> , 31, 193-201  | 4.7 | 6   |
| 11 | Proactive pharmaceutical care interventions decrease patientsSnonadherence to osteoporosis medication. <i>Osteoporosis International</i> , <b>2014</b> , 25, 1807-12   | 5.3 | 27  |
| 10 | Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. <i>Respiratory Research</i> , <b>2014</b> , 15, 66  | 7.3 | 49  |
| 9  | Clinical and economic impact of non-adherence in COPD: a systematic review. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 103-13  | 4.6 | 130 |
| 8  | Impact of multiple-dose versus single-dose inhaler devices on COPD patientsSpersistence with long-acting Eagonists: a dispensing database analysis. <i>Npj Primary Care Respiratory Medicine</i> , <b>2014</b> , 24, 14069 | 3.2 | 13  |
| 7  | Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. <i>Journal of Managed Care Pharmacy</i> , <b>2014</b> , 20, 786-92        |     | 32  |
| 6  | Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. <i>Journal of Managed Care Pharmacy</i> , <b>2014</b> , 20, 722-32                              |     | 15  |
| 5  | The pharmacistsSpotential to provide targets for interventions to optimize pharmacotherapy in patients with asthma. <i>International Journal of Clinical Pharmacy</i> , <b>2013</b> , 35, 1075-82                          | 2.3 | 13  |
| 4  | Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis. <i>Drug Safety</i> , <b>2013</b> , 36, 231-6  | 5.1 | 48  |
| 3  | Persistence with osteoporosis medication among newly-treated osteoporotic patients. <i>Journal of Bone and Mineral Metabolism</i> , <b>2013</b> , 31, 562-70   | 2.9 | 42  |
| 2  | Proactive pharmaceutical care interventions improve patientsSadherence to lipid-lowering medication. <i>Annals of Pharmacotherapy</i> , <b>2013</b> , 47, 1448-56  | 2.9 | 28  |
| 1  | COPD in the working age population: the economic impact on both patients and government.  COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 629-39   | 2   | 35  |